Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Seamless, Phase 1b/2 Multiple Ascending Dose/Proof of Concept Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations

X
Trial Profile

A Seamless, Phase 1b/2 Multiple Ascending Dose/Proof of Concept Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs XTMAB-16 (Primary)
  • Indications Pulmonary sarcoidosis
  • Focus Adverse reactions; Proof of concept
  • Sponsors Xentria
  • Most Recent Events

    • 15 Nov 2023 According to Xentria media release, the first patient being enrolled onto the study by Dr. Peter Sporn at Northwestern Memorial Hospital will add to the breadth of data that will explore the potential of XTMAB-16 in treating sarcoidosis.
    • 15 Nov 2023 According to Xentria media release, Dr. Ogugua Obi is a principal investigator of this study.
    • 02 Oct 2023 Planned initiation date changed from 1 Aug 2023 to 1 Oct 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top